Amendments to the Claims:

1. (Currently Amended) A compound corresponding to the formula (I):

$$(X)m - (Y)y \qquad \qquad (I)$$

in which:

X represents a group selected from: glucose, fructose, mannose, galactose, ribose, maltose, glucosamine, sucrose and lactobionamide, a poly(ethylene oxide) chain comprising consisting of from 30 to 100 ethylene oxide units, a group selected from,

m represents an integer equal to 1, 2 or 3;

Y represents a spacer arm which is intended to link the aromatic nucleus to the

Amdt. dated March 10, 2009

Reply to Office Action of December 15, 2008

hydrophilic X substituents; and

y represents an integer equal to 0 or to 1;

Y' represents a group selected from __O_C___, __NH__C___, __NH__C___NH___,
O___O_NH___, __O__, __s__ an ester function, an amide function, a urea function, a urethane function, an ether bridge or a thioether bridge;

m' is an integer selected from 1 and 2;

X' represents a hydrogen atom or a C₄-C₁₄ alkyl chain which is optionally substituted by one or more fluorine atoms.

- 2. (Previously Presented) The compound as claimed in claim 1, wherein X represents a group selected from: glucose, lactose, manose, galactose, ribose, maltose, glucosamine, sucrose and lactobionamide.
- 3. (Currently Amended) A compound as claimed in claim 1, wherein X represents a group selected from poly(ethylene oxide) chains eomprising consisting of from 50 to 60 units.
- 4. (Previously Presented) A compound as claimed in claim 1, wherein X represents a group selected from

Amdt. dated March 10, 2009

Reply to Office Action of December 15, 2008

5. (Previously Presented) A compound as claimed in claim 1, wherein at least one of the following conditions is satisfied:

X represents a group selected from: lacto-bionamide,

m represents 1;

m' represents 1 or 2;

X' is selected from the groups octyl, decyl, dodecyl and $CF_3(CF_2)_rCH_2CH_2$ -, where $8 \ge r \ge 6$.

6. (Previously Presented) A process for preparing a compound corresponding to the formula (I) as claimed in Claim 1 wherein an aldehyde corresponding to the formula (II) is reacted with a hydroxylamine corresponding to the formula (III) in accordance with scheme 2

Amdt. dated March 10, 2009

Reply to Office Action of December 15, 2008

below:

(II)

HN
$$C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}$$
 $(X)m-(Y)y$

HN $C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}$
 $(X)m-(Y)y$
 $(X)m-(Y)y$

(II)

(II)

Scheme 2

7. (Previously Presented) The process as claimed in claim 6, wherein the compound of the formula (III) is prepared in accordance with a process which is described in scheme 3:

$$O_2N^{-C(CH_3)_{(3-m')}(CH_2Z)_{m'}} + m' HY'X'$$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$
 $O_2N^{-C(CH_3)_{(3-m')}(CH_2-Y'-X')_{m'}}$

Scheme 3

- 8. (Previously Presented) A pharmaceutical composition comprising at least one compound corresponding to the formula (I) as claimed in Claim 1 in a pharmaceutically acceptable excipient.
- 9. (Previously Presented) A method to prevent and/or treat the effects of free radicals in an individual, said method comprising the step of administering a compound corresponding to the formula (I) as claimed in Claim 1 to this individual.

Amdt. dated March 10, 2009

Reply to Office Action of December 15, 2008

10. (Previously Presented) A method to prevent or treat a pathological condition linked to oxidative stress and to the formation of oxygen-containing free radical species, in an individual said method comprising the step of administering to said individual a compound as claimed in claim 1.

- 11. (Previously Presented) The method as claimed in claim 10 for preventing or treating a pathological condition selected from immune and inflammatory diseases, the ischemia-reperfusion syndrome, atherosclerosis, Alzheimer's disease, Parkinson's disease, lesions due to UV and ionizing radiations, Huntington's disease, cancers and cellular aging.
- 12. (Previously Presented) A cosmetic composition, comprising at least one compound corresponding to the formula (I) as claimed in Claim 1 in a cosmetically acceptable excipient.
- 13. (Previously Presented) A cosmetic treatment method for preventing and/or treating the effects of aging, comprising applying to the skin or to the epidermal appendages a composition as claimed in claim 12.
- 14. (Previously Presented) A method of capturing free radicals comprising the step of reacting a free radical with the compound as claimed in Claim 1.
- 15. (Previously Presented) A compound as claimed in claim 1, wherein X represents a group selected from: glucosamine, sucrose and lactobionamide.

16. (Previously Presented) The compound as claimed in claim 1, wherein Y represents a group selected from:

-NH₂-CH₂-,

$$-O-(CH_2)_2-NH-C-$$